COMMON STOCK PURCHASE WARRANT ADAMIS PHARMACEUTICALS CORPORATIONSecurities Agreement • January 26th, 2016 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations
Contract Type FiledJanuary 26th, 2016 Company IndustryTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _______________________, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Issue Date”) and on or prior to 11:59 P.M. on the five (5) year anniversary of the Issue Date or, if such day is not a Trading Day, on the next Trading Day (the “Termination Date”), but not thereafter, to subscribe for and purchase from Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), up to _______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of, at the election of the Holder, either (i) Common Stock, (ii) Series A-1 Convertible Preferred Stock, par value $0.0001 par value per share (“Preferred Stock”), or (iii) a combination of Common Stock and Preferred Stock. The purchase price of one share of Common Stock or Preferred Stock under this Warr
PURCHASE AGREEMENTPurchase Agreement • January 26th, 2016 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • New York
Contract Type FiledJanuary 26th, 2016 Company Industry JurisdictionTHIS PURCHASE AGREEMENT (“Agreement”) is made as of January 26, 2016, by and among Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), and each entity named on the signature page of this Agreement (each an “Investor” and collectively, the “Investors”).
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 26th, 2016 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • New York
Contract Type FiledJanuary 26th, 2016 Company Industry JurisdictionThis Amended and Restated Registration Rights Agreement (the “Agreement”) is dated as of January 26, 2016 (the “Agreement Date”) and is entered into by and among Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), and the “Investors” named in that certain Purchase Agreement dated August 19, 2014 by and between the company and each of the Investors (the “2014 Purchase Agreement”) and that certain Purchase Agreement dated the date hereof and entered into by and between the Company and each of the Investors (the “2016 Purchase Agreement” and collectively with the 2014 Purchase Agreement, “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement, unless otherwise defined herein.